Advanced glycation end products: sparking the development of diabetic vascular injury.
暂无分享,去创建一个
Ann Marie Schmidt | J. Beckman | M. Creager | A. Schmidt | Mark A Creager | Joshua A Beckman | Alison Goldin | Alison H. Goldin
[1] J. Baynes,et al. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.
[2] Chia Bin Siak,et al. Identification of p90, a Prominent Tyrosine-phosphorylated Protein in Fibroblast Growth Factor-stimulated Cells, as 80K-H (*) , 1996, The Journal of Biological Chemistry.
[3] M. Cooper,et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. , 2004, Diabetes.
[4] J. Uribarri,et al. High Levels of Dietary Advanced Glycation End Products Transform Low-Dersity Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients , 2004, Circulation.
[5] K. O. Elliston,et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.
[6] E. Tsilibary,et al. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. , 1988, The Journal of biological chemistry.
[7] T. Watanabe,et al. Nitric oxide inhibits the formation of advanced glycation end products. , 2000, Kidney international.
[8] S. Narumiya,et al. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. , 2001, Biochemical and biophysical research communications.
[9] Merlin C. Thomas,et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.
[10] G. Remuzzi,et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. , 1998, The Journal of clinical investigation.
[11] W. Hurley,et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.
[12] V. Monnier,et al. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. , 1989, The Journal of biological chemistry.
[13] J. Baynes,et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.
[14] J. Uribarri,et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. , 2003, Journal of the American Society of Nephrology : JASN.
[15] R. Ramasamy,et al. Protein Glycation: A Firm Link to Endothelial Cell Dysfunction , 2004, Circulation research.
[16] R. G. Paul,et al. The effect of advanced glycation end-product formation upon cell-matrix interactions. , 1999, The international journal of biochemistry & cell biology.
[17] Alan W. Stitt,et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat , 2004, Diabetologia.
[18] S. Eguchi,et al. The role of reactive oxygen species in insulin signaling in the vasculature. , 2005, Antioxidants & redox signaling.
[19] E. Tsilibary,et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. , 1992, The Journal of biological chemistry.
[20] P. Guillausseau,et al. Rapid Publication , 1971, Nature.
[21] R. de Caterina,et al. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.
[22] R. de Caterina,et al. Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.
[23] R. Khalifah,et al. Modification of Proteins In Vitro by Physiological Levels of Glucose , 2003, Journal of Biological Chemistry.
[24] G. A. Limb,et al. Induction of TNF alpha and IL-1 beta mRNA in monocytes by methylglyoxal- and advanced glycated endproduct-modified human serum albumin. , 1997, Biochemical Society transactions.
[25] K. Ikeda,et al. Accumulation of Nσ-(Carboxy-methyl)lysine and Changes inGlomerular Extracellular MatrixComponents in Otsuka Long-EvansTokushima Fatty Rat:A Model of Spontaneous NIDDM , 1998, Nephron.
[26] G. Kovacs. Molecular genetics of human renal cell tumours. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] D. Kass,et al. Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.
[28] Merlin C. Thomas,et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. , 2002, Diabetes.
[29] M. Nangaku,et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.
[30] G. Kreibich,et al. Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein , 1992, Cell.
[31] Paul J Thornalley,et al. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. , 2005, Diabetes care.
[32] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[33] S. Horiuchi,et al. Pathological Roles of Advanced Glycation End Product Receptors SR‐A and CD36 , 2005, Annals of the New York Academy of Sciences.
[34] R. Bucala,et al. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. , 1992, The Journal of clinical investigation.
[35] M. Brownlee,et al. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.
[36] E. Howard,et al. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. , 1996, Experimental cell research.
[37] K. Wrobel,et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with Type 2 diabetes mellitus , 2005, Journal of endocrinological investigation.
[38] T. Sawamura,et al. Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end products (AGE) , 2002, FEBS letters.
[39] A. Hata,et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. , 2000, Biochemical and biophysical research communications.
[40] C. Heizmann,et al. The S100 family of EF-hand calcium-binding proteins: functions and pathology. , 1996, Trends in biochemical sciences.
[41] H. Huttunen,et al. Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.
[42] H. Shimano,et al. FEEL-1 and FEEL-2 Are Endocytic Receptors for Advanced Glycation End Products* , 2003, The Journal of Biological Chemistry.
[43] H. Rasmussen,et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. , 1995, Kidney international.
[44] T. Kislinger,et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.
[45] P. Fasching,et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. , 2000, Diabetes.
[46] M. Morales,et al. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. , 2004, Life sciences.
[47] Masayoshi Takeuchi,et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[48] T. Lyons,et al. Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.
[49] Michael Stumvoll,et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. , 2003, Diabetes.
[50] A. Schmidt,et al. RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes , 2000, Trends in Endocrinology & Metabolism.
[51] T. Kislinger,et al. N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.
[52] E. Schleicher,et al. In-Vitro Carboxymethylation of Low Density Lipoprotein Alters its Metabolism Via the High-Affinity Receptor , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[53] M. Simionescu,et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.
[54] M. Steffes,et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.
[55] A. Schmidt,et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.
[56] 久代 昌彦. Accumulation of N[e]-(Carboxymethyl) lysine and changes in glomerular extracellular matrix components in Otsuka long-evans Tokushima fatty rat : a model of spontaneous NIDDM , 1999 .
[57] A. Schmidt,et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.
[58] Alan W. Stitt,et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.
[59] J. Baynes,et al. Role of the Maillard Reaction in Aging of Tissue Proteins , 1998, The Journal of Biological Chemistry.
[60] A. Cerami,et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[61] E. Kohner,et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] J. Uribarri,et al. Advanced glycoxidation end products in commonly consumed foods. , 2004, Journal of the American Dietetic Association.
[63] T. Oegema,et al. Release of Glomerular Heparan-35SO4 Proteoglycan by Heparin From Glomeruli of Streptozocin-Induced Diabetic Rats , 1989, Diabetes.
[64] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[65] Mark E. Williams,et al. Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy , 2004, American Journal of Nephrology.
[66] S. Horiuchi,et al. Scavenger receptors for oxidized and glycated proteins , 2003, Amino Acids.
[67] J. Baynes,et al. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. , 1992, Archives of biochemistry and biophysics.
[68] E. Snell. THE VITAMIN ACTIVITIES OF "PYRIDOXAL" AND "PYRIDOXAMINE" , 1944 .
[69] M. Fujishima,et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. , 1998, Atherosclerosis.
[70] A. Cerami,et al. Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein , 1985, Diabetes.
[71] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[72] B. Shilton,et al. Role of fructose in glycation and cross-linking of proteins. , 1988, Biochemistry.
[73] T. Ikemura,et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. , 1994, Genomics.
[74] T. Kislinger,et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.
[75] G. Striker,et al. Administration of AGEs in vivo induces extracellular matrix gene expression. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[76] G. Jerums,et al. Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.
[77] Yong Ming Li,et al. Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.
[78] S. Horiuchi,et al. CD36 is not involved in scavenger receptor-mediated endocytic uptake of glycolaldehyde- and methylglyoxal-modified proteins by liver endothelial cells. , 2005, Journal of biochemistry.
[79] P. Riederer,et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression , 1999 .
[80] M. Peppa,et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[81] J. Baynes,et al. Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.
[82] H. Vlassara. The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.
[83] A. Schmidt,et al. The dark side of glucose , 1995, Nature Medicine.
[84] K. Tsuda,et al. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats , 2002, Journal of hypertension.
[85] A. Schmidt,et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[87] H. Hammes,et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.
[88] M. Brownlee,et al. Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine , 1992, Diabetes.
[89] E. Snell. The vitamin B6 group. 5. The reversible interconversion of pyridoxal and pyridoxamine by transamination reaction. , 1945 .
[90] M. Suthanthiran,et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.
[91] K. Kuwabara,et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[92] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[93] T. Miyata,et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.
[94] T. Kislinger,et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.
[95] H. Hammes,et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[96] T. Wascher,et al. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells. , 1999, Diabetes.
[97] R. Bucala,et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.
[98] H. Gerlach,et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.
[99] Merlin C. Thomas,et al. A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.
[100] R. Bucala,et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[101] E. Frohlich,et al. Crosslink breakers: a new approach to cardiovascular therapy , 2004, Current opinion in cardiology.
[102] A. Schmidt,et al. Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.
[103] M. Andrassy,et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.
[104] E. Friedman,et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. , 1992, Science.
[105] Alan W. Stitt,et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[106] Paul J Thornalley,et al. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. , 1994, The Journal of biological chemistry.
[107] A. Schmidt,et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.
[108] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[109] S. Grundy,et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[110] D. Metzler,et al. A General Mechanism for Vitamin B6-catalyzed Reactions1 , 1954 .
[111] S. Horiuchi,et al. Scavenger Receptor Class B Type I-mediated Reverse Cholesterol Transport Is Inhibited by Advanced Glycation End Products* , 2001, The Journal of Biological Chemistry.
[112] F. Pomero,et al. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose , 2001, Acta Diabetologica.
[113] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[114] H. Makino,et al. Roles of advanced glycation end-products in the progression of diabetic nephropathy. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[115] J. Baynes,et al. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.
[116] Alan W. Stitt,et al. Atherogenesis and Advanced Glycation: Promotion, Progression, and Prevention a , 1997, Annals of the New York Academy of Sciences.
[117] A. Schmidt,et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.
[118] J. Sasaki,et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. , 2000, Atherosclerosis.
[119] Suk-Hee Yu,et al. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. , 1999, Diabetes research and clinical practice.
[120] E. Eikenberry,et al. Glycation induces expansion of the molecular packing of collagen. , 1988, Journal of molecular biology.
[121] D. Kass. Getting Better Without AGE New Insights Into the Diabetic Heart , 2003, Circulation research.
[122] R. Ramasamy,et al. RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[123] E. Tsilibary,et al. Laminin Alterations After In Vitro Nonenzymatic Glycosylation , 1990, Diabetes.
[124] Hiroshi Yamamoto,et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.
[125] M. Cooper,et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. , 2002, Diabetes.
[126] N. Taniguchi,et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis. , 2001, Cardiovascular research.
[127] Alan W. Stitt,et al. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. , 1998, Diabetes.
[128] T. Luther,et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. , 1997, Circulation.
[129] M Duriez,et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[130] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[131] K. Otero,et al. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. , 2000, Circulation research.
[132] A. Schmidt,et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[133] M. Brownlee,et al. Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.